Type 2 diabetes, thiazolidinediones, and cardiovascular risk

British Journal of General Practice

Volumn 59, Issue 564, 2009, Pages 520-524

  Taylor, Clare ^a   Hobbs, F D Richard ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cardiovascular risk; Glitazones; Heart failure; Thiazolidinediones; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ABDOMINAL DISCOMFORT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FOOD AND DRUG ADMINISTRATION; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; META-ANALYSIS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 67650821922     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp09X453440     Document Type: Article

References (29)

1. Warrell D, Cox TM, Firth J, et al. Oxford textbook of medicine. Oxford: Oxford University Press, 2004.
2. International Diabetes Federation. Diabetes atlas. Foreword http://www.eatlas.idf.org/news.asp?newsid=2007731153431 (accessed 20 Apr 2009).
3. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332(7533): 73-78. (Pubitemid 43099245)
4. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853. (Pubitemid 28416718)
5. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11): 1106-1118.
6. Gitlin N, Neil LJ, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129(1): 36-38. (Pubitemid 28304650)
7. Clifford RJ. The rosiglitazone story - lessons from an FDA advisory committee meeting. N Engl J Med 2007; 357(9): 844-846. (Pubitemid 47347317)
8. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368(9541): 1096-1105.
9. Kahn SE, Haffner SM, Heise MA, et al for the ADOPT Study Group. Glycaemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 2006; 355(23): 2427-2443.
10. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 1-15. (Pubitemid 46919772)
11. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007; 356(24): 2522-2524.
12. Richter B, Bandeira Echtler E, Bergerhoff K et al. Rosiglitazone for type 2 diabetes mellitus (Review). Cochrane Database Syst Rev 2007; 3: CD006063. (Pubitemid 351805644)
13. Home PD, Pocock SJ, Beck-Nielsen H, et al for the RECORD Study Group. Rosiglitazone Evaluated for Cardiovascular Outcomes - an interim analysis. N Engl J Med 2007; 357(1): 1-11.
14. Dragie HJ, Hildebrandt PR, Riegger GA, et al. A randomised, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class 1 or 2 heart failure. J Am Coll Cardiol 2007; 49(16): 1696-1704.
15. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone - a meta-analysis. JAMA 227; 298(10): 1189-1195.
16. Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalisation for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007; 16(10): 1065-1071. (Pubitemid 350020057)
17. Dormandy JA, Charbonnel B, Eckland DJA, et al for the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279-1289.
18. Erdmann E, Dormandy JA, Charbonnel B, et al for the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49(17): 1772-1780. (Pubitemid 46629127)
19. Wilcox R, Bousser MG, Betteridge J, et al for the PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke. Stroke 2007; 38(3): 865-873.
20. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - a meta-analysis of randomized trials. JAMA 2007; 298(10): 1180-1188. (Pubitemid 47403104)
21. Nissen SE, Nicholls SJ, Wolski K,et al for the PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. JAMA 2008; 299(13): 1561-1573.
22. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - a randomized trial. JAMA 2006; 296(21): 2572-2581. (Pubitemid 44903861)
23. Steg PG, Marre M. Does PERISCOPE provide a new perspective on diabetic treatment? JAMA 2008; 299(13): 1603-1604.
24. Lago RM, Singh PP, Nesto R. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370(9593): 1129-1136. (Pubitemid 47464583)
25. US Food and Drug Administration Center for Drug Evaluation and Research. Information for healthcare professionals: pioglitazone HCI (marketed as Actos, Actoplus Met, and Duetact). Rockville: FDA, 2007. http://www.fda.gov/cder/drug/ InfoSheets/HCP/pioglitazoneHCP.htm (accessed 20 Apr 2009).
26. US Food and Drug Administration. Highlights of prescribing information: Avandia (rosiglitazone maleate) tablets. Rockville: FDA, 2007.http://www.fda. gov/cder/foi/label/2007/021071s031Ibl.pdf (accessed 20 Apr 2009).
27. European Medicines Agency. Press release: European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone. London: European Medicines Agency, 2007. http://vww.emea.europa.eu/pdfs/human/ press/pr/48427707en.pdf (accessed 20 Apr 2009).
28. European Medicines Agency. Press release:EMEA recommends new warnings and contraindications for rosiglitazone. London: European Medicines Agency, 2008. http://www.emea.europa.eu/humandocs/PDFs/EPAR/avaglini/4223208 en.pdf (accessed 20 Apr 2009).
29. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes (update). Clinical Guideline 66. London: National Institute for Health and Clinical Excellence, 2008. http://www.nice.org.uk/Guidance/CG66 (accessed 20 Apr 2009).